Reading: Wastewater Testing and Community Drug Monitoring

The White House’s National Drug Control Strategy, published on May 4, 2026, formalizes a plan to implement wastewater testing at national scale to deliver near real-time data on illegal drug use. While the policy seeks to modernize surveillance and decision making, it also requires careful integration with existing public health systems to be effective.

Wastewater-based epidemiology measures parent drugs and their metabolites in sewage influent; laboratories typically use liquid chromatography–tandem mass spectrometry and high-resolution mass spectrometry to identify and quantify these compounds, and results are normalized by wastewater flow and estimated population. However, estimates are subject to uncertainty because in-sewer degradation, sampling design, and population size calculations can alter measured loads, so interpretation often requires expertise and standardized methods.

Applications have ranged from citywide monitoring to targeted studies near universities and event venues, and automated sampling can reveal temporal patterns. International multi-city studies and recent method developments, including portable on-site extraction and high-resolution approaches, have improved timeliness and the range of compounds that can be detected. The U.S. Centers for Disease Control and Prevention has invested in wastewater surveillance infrastructure and supports six wastewater Centers of Excellence, which provide training, testing capacity, and data tools that could be adapted for drug monitoring.

Nevertheless, ethicists and public health bodies have stressed group privacy concerns and the risk of stigmatizing communities if data are used at very small scales or by law enforcement. Consequently, transparency, oversight, and strong limits on non‑public health uses will be essential if wastewater testing is to yield public health benefits without undue harm.